149 related articles for article (PubMed ID: 28537063)
1. [Consensus opinion on antifungal prophylaxis in haematologic patients: Results of the PROMIC project].
Vázquez López L; Villaescusa de la Rosa T; de la Cámara R; Espigado I; Grau Cerrato S; Jurado M; Rovira M; Salavert M; Serrano Simonneau D; Solano Vercet C; Ruiz Camps I
Rev Esp Quimioter; 2017 Jun; 30(3):213-223. PubMed ID: 28537063
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
3. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis.
Biehl LM; Vehreschild JJ; Liss B; Franke B; Markiefka B; Persigehl T; Bücker V; Wisplinghoff H; Scheid C; Cornely OA; Vehreschild MJ
J Antimicrob Chemother; 2016 Sep; 71(9):2634-41. PubMed ID: 27317443
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
[TBL] [Abstract][Full Text] [Related]
5. Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects.
Akan H; Antia VP; Kouba M; Sinkó J; Tănase AD; Vrhovac R; Herbrecht R
J Antimicrob Chemother; 2013 Nov; 68 Suppl 3():iii5-16. PubMed ID: 24155144
[TBL] [Abstract][Full Text] [Related]
6. A network meta-analysis of primary prophylaxis for invasive fungal infection in haematological patients.
Leonart LP; Tonin FS; Ferreira VL; Penteado STS; Wiens A; Motta FA; Pontarolo R
J Clin Pharm Ther; 2017 Oct; 42(5):530-538. PubMed ID: 28620958
[TBL] [Abstract][Full Text] [Related]
7. Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field.
Douglas AP; Slavin MA
Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1165-1177. PubMed ID: 27710140
[TBL] [Abstract][Full Text] [Related]
8. Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study.
Nachbaur D; Angelova O; Orth-Höller D; Ditlbacher A; Lackner M; Auberger J; Lass-Flörl C
Eur J Haematol; 2015 Mar; 94(3):258-64. PubMed ID: 25082655
[TBL] [Abstract][Full Text] [Related]
9. [Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].
Salavert M; Jarque I
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():43-9. PubMed ID: 21420577
[TBL] [Abstract][Full Text] [Related]
10. EPICO 2.0 project. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations.
Zaragoza R; Ferrer R; Maseda E; Llinares P; Rodriguez A;
Rev Iberoam Micol; 2014; 31(3):157-75. PubMed ID: 25113990
[TBL] [Abstract][Full Text] [Related]
11. [Bacteraemia and infection of the vascular catheter in the haematology patient: positioning and management based on the Delphi method].
Azanza-Perea JR; López-Jiménez J; Parody-Porras R; Salavert-Lletí M; Solano C; Valcárcel D; Vallejo-Llamas C; Vázquez-López L; Rivas-González P
Rev Esp Quimioter; 2016 Feb; 29(1):15-24. PubMed ID: 26875567
[TBL] [Abstract][Full Text] [Related]
12. Pharmacist review of high-risk haematology outpatients to improve appropriateness of antifungal prophylaxis.
Reslan Z; Lindsay J; Kerridge I; Gellatly R
Int J Clin Pharm; 2020 Dec; 42(6):1412-1418. PubMed ID: 33009604
[TBL] [Abstract][Full Text] [Related]
13. Defining standards of CARE for invasive fungal diseases in adult haematology patients: antifungal prophylaxis versus treatment.
Barnes R; Rogers T; Maertens J
J Antimicrob Chemother; 2019 Mar; 74(Suppl 2):ii21-ii26. PubMed ID: 31222310
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry.
Vehreschild JJ; Sieniawski M; Reuter S; Arenz D; Reichert D; Maertens J; Böhme A; Silling G; Martino R; Maschmeyer G; Rüping MJ; Ullmann AJ; Cornely OA
Int J Antimicrob Agents; 2009 Nov; 34(5):446-50. PubMed ID: 19700265
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R
Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571
[TBL] [Abstract][Full Text] [Related]
16. EPICO 2.0 PROJECT. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations.
Zaragoza R; Ferrer R; Maseda E; Llinares P; Rodríguez A;
Rev Esp Quimioter; 2014 Sep; 27(3):196-212. PubMed ID: 25229375
[TBL] [Abstract][Full Text] [Related]
17. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
18. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
Oyake T; Kowata S; Murai K; Ito S; Akagi T; Kubo K; Sawada K; Ishida Y
Eur J Haematol; 2016 Jun; 96(6):602-9. PubMed ID: 26216048
[TBL] [Abstract][Full Text] [Related]
19. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Stemler J; Mellinghoff SC; Khodamoradi Y; Sprute R; Classen AY; Zapke SE; Hoenigl M; Krause R; Schmidt-Hieber M; Heinz WJ; Klein M; Koehler P; Liss B; Koldehoff M; Buhl C; Penack O; Maschmeyer G; Schalk E; Lass-Flörl C; Karthaus M; Ruhnke M; Cornely OA; Teschner D
J Antimicrob Chemother; 2023 Aug; 78(8):1813-1826. PubMed ID: 37311136
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis for aspergillosis in patients with haematological malignancies: pros and cons.
Busca A; Pagano L
Expert Rev Anti Infect Ther; 2018 Jul; 16(7):531-542. PubMed ID: 30033822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
